key: cord-0687465-canpn48c authors: Kurhade, Chaitanya; Zou, Jing; Xia, Hongjie; Cai, Hui; Yang, Qi; Cutler, Mark; Cooper, David; Muik, Alexander; Jansen, Kathrin U.; Xie, Xuping; Swanson, Kena A.; Shi, Pei-Yong title: Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine date: 2022-03-28 journal: bioRxiv DOI: 10.1101/2022.03.24.485633 sha: 8f2740096785d2b3fe9476732427b007b578f515 doc_id: 687465 cord_uid: canpn48c The newly emerged Omicron SARS-CoV-2 has 3 distinct sublineages: BA.1, BA.2, and BA.3. BA.1 accounts for the initial surge and is being replaced by BA.2, whereas BA.3 is at a low prevalence at this time. Here we report the neutralization of BNT162b2-vaccinated sera (collected at 1 month after dose 3) against the three Omicron sublineages. To facilitate the neutralization testing, we engineered the complete BA.1, BA.2, or BA.3 spike into an mNeonGreen USA-WA1/2020 SRAS-CoV-2. All BNT162b2-vaccinated sera neutralized USA-WA1/2020, BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s with titers of >20; the neutralization geometric mean titers (GMTs) against the four viruses were 1211, 336, 300, and 190, respectively. Thus, the BA.1-, BA.2-, and BA.3-spike SARS-CoV-2s were 3.6-, 4.0-, and 6.4-fold less efficiently neutralized than the USA-WA1/2020, respectively. Our data have implications in vaccine strategy and understanding the biology of Omicron sublineages. in vaccine strategy and understanding the biology of Omicron sublineages. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has recently emerged as the fifth variant of concern (VOC) after the previous Alpha, Beta, Gamma, and Delta VOCs. The Omicron variant includes 3 sublineages: BA. 1 (Fig. S1a) , laboratory results are urgently needed to evaluate the susceptibility of the three Omicron sublineages to vaccine-elicited neutralization. BNT162b2 is an mRNA vaccine that encodes a stabilized prefusion full-length spike glycoprotein from the original SARS-CoV-2 Wuhan-Hu-1 isolate. BNT162b2 mRNA has been approved for vaccination of people Thus, we should closely monitor the prevalence of BA.3 during surveillance. Despite the reduced neutralization of Omicron sublineages, other immune effectors, such as T cells and non-neutralizing antibodies that mediate antibody-dependent cytotoxicity, also contribute to the protection against severe COVID-19. The majority of T cell epitopes after vaccination or natural infection are preserved against Omicron spikes. 9 Indeed, 3 doses of BNT162b2 has conferred efficacy against Omicron disease; however, recent real world effectiveness data showed a waning of protection against symptomatic infection caused by Omicron. Waning of protection was more modest against severe disease caused by Omicron, with overall efficacy remaining high 3 to 6 months after dose 3. [10] [11] [12] [13] [14] Studies are underway to determine the extended durability of the PD3 neutralization against Omicron sublineages and future variants. These laboratory investigations, together with real world vaccine effectiveness data, will continue to guide 4 th dose vaccine strategy for optimal breadth and duration of protection. were constructed by engineering the complete spike gene from Omicron sublineages into an infectious cDNA clone of mNG USA-WA1/2020 15 (Figure S1a) . All spike mutations, deletions, and insertions were introduced into the infectious cDNA clone of mNG USA-WA1/2020 using PCR-based mutagenesis as previously described. 16 The BA. (Figure S1b) . We sequenced the complete spike gene of the P1 virus to ensure no undesired mutations. Only the P1 viruses were used for neutralization test. The protocols for the mutagenesis of mNG SARS-CoV-2 and virus production were reported previously. 17 To determine the specific infectivity, we quantified the P1 virus stocks for their fluorescent focus units (FFU) and genomic RNA contents by fluorescent focus assay on Vero E6 cells and RT-qPCR, respectively. The methods for fluorescent focus assay and RT-qPCR were reported previously. 4, 18 The specific infectivity of each virus was measured by the genomic RNA-to-FFU ratios (genome/FFU). Neutralization titers of human sera were measured by FFRNT using the USA-WA1/2020, BA. Figure S3 as previously reported. 19 The BA.1-, BA.2-, and BA.3-spike mNG SARS-CoV-2s were produced by engineering the complete Omicron spike genes into the mNG USA-WA1/2020. 15 Each data point represents the geometric mean FFRNT 50 obtained with a serum specimen against the indicated virus, as detailed in Tables S1. The neutralization titers for BA.1-, BA.2-, and BA.3-spike mNG SARS-CoV-2s were determined in duplicate assays; the FFRNT 50 s for USA-WA1/2020 mNG SARS-CoV-2 were determined in two independent experiments, each with duplicate assays; the geometric means were presented. The bar heights and the numbers above indicate geometric mean titers. The whiskers indicate 95% confidence intervals. The dotted line indicates the limit of detection of FFRNT 50 . Statistical analysis was performed with the use of the Wilcoxon matched-pairs signed-rank test. The statistical significances of the differences between geometric mean titers against the USA-WA1/2020 and Omicron BA.1-, BA.2-, or BA.3-spike SARS-CoV-2 are all p < 0.0001. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households Anne von Gottberg & Cohen, C. Clinical severity of Omicron sub-lineage BA.2 compared to BA.1 in South Africa Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2 Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection Antibody evasion properties of SARS-CoV-2 Omicron sublineages Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. medRxiv The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry Nationwide study on SARS-CoV-2 transmission within households from lockdown to reopening, Denmark Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States Waning effectiveness of COVID-19 vaccines Pfizer-Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant COVID-19 vaccine surveillance report -Week An Infectious cDNA Clone of SARS-CoV-2 Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera Engineering SARS-CoV-2 using a reverse genetic system Spike mutation D614G alters SARS-CoV-2 fitness SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 We thank the Pfizer-BioNTech clinical trial C4591001 and NCT04368728 participants, from whom the post-immunization human sera were obtained. We thank the many colleagues at Pfizer and BioNTech who developed and produced the BNT162b2 vaccine.